Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,170.0 million
Deal Type : Licensing Agreement
Novartis Pays Baiyu $70M, with $1.1B Chaser, for Cancer Prospect
Details : The deal covers the global rights to a small molecule discovered by a Chinese biotech that has built a business around botanical drugs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $70.0 million
October 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,170.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Takeda Pharmaceutical
Deal Size : $1,300.0 million
Deal Type : Agreement
Ascentage Pharma Received US$100 Million Option Payment from Takeda
Details : Ascentage and Takeda entered into an agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib) for Chronic Myeloid Leukemia.
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 07, 2024
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Takeda Pharmaceutical
Deal Size : $1,300.0 million
Deal Type : Agreement
Lead Product(s) : 225-Ac
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Yonghe Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Actinium-225 is an alpha emitting radioactive particle that has high energy density acting at distances of just a few cell widths. At these short distances, radiation can be restricted to the cancer cells of interest with minimal risk to nearby normal he...
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
December 27, 2022
Lead Product(s) : 225-Ac
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Yonghe Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : $1,407.0 million
Deal Type : Licensing Agreement
China’s Kelun Pharma Jumps on Licensing New Cancer Drug to Holland’s Merck Sharp & Dohme
Details : The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing of upfront cash in exchange for ex-China rights to a “macromolecular tumor project".
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : $47.0 million
May 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : $1,407.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Focus-X Therapeutics
Deal Size : $245.0 million
Deal Type : Acquisition
Details : Focus-X is developing targeted radiopharmaceuticals-based therapeutic to treat cancer based on its proprietary peptide engineering technology. Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from co...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Focus-X Therapeutics
Deal Size : $245.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As a result of the collaboration, Adagene discovered antibodies that Dr. Child’s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney cancer in adults, according t...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : LaNova Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Asymchem and LaNova Medicines Enter into Partnership Agreement, Expanding Biological Capabilities
Details : The partnership between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : LaNova Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : KM257
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Xuanzhu Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Acquisition
Xuanzhu Biopharm Acquires Combio Pharmaceutical
Details : Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.
Product Name : KM257
Product Type : Antibody
Upfront Cash : Undisclosed
January 27, 2021
Lead Product(s) : KM257
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Xuanzhu Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Apricot Capital
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The series A financing will help in accelerating Medilink's innovative pipeline development and to support its unique conjugate technology platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 03, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Apricot Capital
Deal Size : $50.0 million
Deal Type : Series A Financing
Lead Product(s) : FCN-338
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Eli Lilly
Deal Size : $440.0 million
Deal Type : Licensing Agreement
Details : Lilly gains exclusive rights to develop and sell FCN-338 in all countries and regions except for Mainland China, Macao, and Hong Kong. Fochon reserves all right to research, develop, register, manufacture, and market FCN-338 in Mainland China, Macao, and...
Product Name : FCN-338
Product Type : Other Small Molecule
Upfront Cash : $40.0 million
October 30, 2020
Lead Product(s) : FCN-338
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Eli Lilly
Deal Size : $440.0 million
Deal Type : Licensing Agreement